Copyright
©The Author(s) 2018.
World J Gastroenterol. Jul 7, 2018; 24(25): 2764-2775
Published online Jul 7, 2018. doi: 10.3748/wjg.v24.i25.2764
Published online Jul 7, 2018. doi: 10.3748/wjg.v24.i25.2764
Study | Follow-up duration (wk) | Anti-TNFα treatment | Placebo | ||
N1 | N2 | N1 | N2 | ||
Adalimumab | |||||
Hanauer et al[44], 2006 | 4 | 0 | 225 | 0 | 74 |
Colombel et al[47], 2007 | 52 | 2 | 517 | 0 | 261 |
Sandborn et al[35], 2007a | 52 | 0 | 37 | 0 | 18 |
Sandborn et al[34], 2007b | 4 | 0 | 159 | 0 | 166 |
Rutgeerts et al[37], 2012 | 48 | 0 | 64 | 0 | 65 |
Watanabe et al[28], 2012 | 52 | 0 | 25 | 0 | 25 |
Watanabe et al[28], 2012 | 4 | 0 | 67 | 0 | 23 |
Total | 1094 | 632 | |||
Certolizumab pegol | |||||
Winter et al[27], 2004 | 12 | 0 | 66 | 0 | 24 |
Schreiber et al[30], 2005 | 20 | 0 | 145 | 0 | 73 |
Sandborn et al[36], 2007c | 26 | 0 | 331 | 0 | 329 |
Schreiber et al[31], 2007 | 20 | 1 | 216 | 0 | 212 |
Sandborn et al[33], 2011 | 6 | 0 | 223 | 0 | 215 |
UCB Pharma[42], 2014 | 36 | 0 | 87 | 0 | 87 |
Total | 1068 | 940 | |||
Infliximab | |||||
Targan et al[29], 1997 | 12 | 0 | 83 | 0 | 25 |
D’Haens et al[46], 1999 | 4 | 0 | 22 | 0 | 8 |
Present et al[41], 1999 | 18 | 0 | 63 | 0 | 31 |
Rutgeerts et al[38], 1999 | 36 | 0 | 37 | 0 | 36 |
Hanauer et al[45], 2002 | 44 | 1 | 385 | 0 | 188 |
Sands et al[32], 2004 | 40 | 0 | 139 | 0 | 143 |
Lémann et al[43], 2006 | 52 | 0 | 57 | 0 | 58 |
Colombel et al[48], 2010 | 30 | 1 | 169 | 0 | 170 |
Regueiro et al[40], 2011 | 52 | 0 | 11 | 0 | 13 |
Regueiro et al[39], 2016 | 104 | 1 | 147 | 0 | 150 |
Total | 1113 | 822 |
n | Risk estimate | 95%CI | P value | |
Risk difference odds ratio | 23 | 0.028 | (0.0011, 0.055) | 0.042 |
Including Double-Zero Studies | 23 | 4.85 | (1.02, 22.99) | 0.047 |
Excluding Double-Zero Studies | 5 | 5.85 | (1.13, 30.38) | 0.036 |
Incidence of TB with TNFα treatment (cases/person-years)1 | Number of patients treated to see one TB Case in one year | |
Based on risk difference | 177/100000 | 565 |
Based on relative odds estimated with background correction | 97/100000 | 1031 |
Based on relative odds estimated without background correction | 117/100000 | 855 |
- Citation: Cao BL, Qasem A, Sharp RC, Abdelli LS, Naser SA. Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα). World J Gastroenterol 2018; 24(25): 2764-2775
- URL: https://www.wjgnet.com/1007-9327/full/v24/i25/2764.htm
- DOI: https://dx.doi.org/10.3748/wjg.v24.i25.2764